Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease-Reference-Cited by-同舟云学术

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease

Published:2004-10-18 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Deane Katherine¹,Spieker Sybille²,Clarke Carl E³

Affiliation:

1. Newcastle University; Institute of Health & Society; 21 Claremont Place Newcastle-upon-Tyne UK NE2 4AA.

2. Marburg Germany

3. City Hospital, Sandwell and West Birmingham Hospitals NHS Trust; Department of Neurology; Dudley Road Birmingham West Midlands UK B18 7QH

Publisher

Wiley

Subject

Pharmacology (medical)

Reference61 articles.

1. Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-Carbidopa

2. Catechol-O-methytransferase inhibition with tolcapone reduces the 'wearing-off' phenomenon and levodopa requirements in fluctuating Parkinsonian patients;Baas;Journal of Neurology, Neurosurgery and Psychiatry,1997

3. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomized, placebo-controlled, double-blind six-month study;Brooks;Journal of Neurology, Neurosurgery and Psychiatry,2003

4. The UK-Irish double-blind study of entacapone in Parkinson's disease;Sagar;Movement Disorders,2000

5. Efficacy and safety of entacapone in non-fluctuating and fluctuating Parkinsonian patients. The UK-Irish long-term multicentre Study;Sagar;European Journal of Neurology,2000

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacotherapy of motor symptoms in early and mid-stage Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology;Journal of Neurology;2024-08-29

2. Entacapone Nanoemulsion: Formulation Design, Optimization, and Evaluation;2024-03-14

3. Morbus Parkinson;Arzneiverordnungs-Report 2023;2023

4. Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence;Frontiers in Pharmacology;2022-04-07

5. Different Catechol-O-Methyl Transferase Inhibitors in Parkinson's Disease: A Bayesian Network Meta-Analysis;Frontiers in Neurology;2021-09-24